Publications by authors named "Ryan Kofron"

Claim this Profile
C
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.
Meredith E Clement, Brett Hanscom, Daniel Haines, Jose A Bazan, Nuntisa Chotirosniramit, Ryan Kofron

Clin Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis.
Raphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, Mark A Marzinke, Estelle Piwowar-Manning, Ryan Kofron

N Engl J Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Raphael J Landovitz, Brett S Hanscom, Meredith E Clement, Ha V Tran, Esper G Kallas, Ryan M Kofron

Lancet HIV· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Mark A Marzinke, Jessica M Fogel, Zhe Wang, Estelle Piwowar-Manning, Ryan Kofron

Antimicrob Agents Chemother· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
Susan H Eshleman, Jessica M Fogel, Elias K Halvas, Estelle Piwowar-Manning, Mark A Marzinke, Ryan Kofron

J Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California.
Adiba Hassan, Harold Glenn San Agustin, Leah Burke, Ryan Kofron, Katya Corado

J Viral Hepat· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, Gordon Chau, Vanessa Cummings, Ryan Kofron

J Infect Dis· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project.
Jill Blumenthal, Raphael Landovitz, Sonia Jain, Feng He, Ryan Kofron

AIDS Patient Care STDS· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, Estelle Piwowar-Manning, Maoji Li, Ryan Kofron

J Infect Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
Jill Blumenthal, Sonia Jain, Feng He, K Rivet Amico, Ryan Kofron

Clin Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Raphael J Landovitz, Deborah Donnell, Meredith E Clement, Brett Hanscom, Leslie Cottle, Ryan M Kofron

N Engl J Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM.
Cheríe S Blair, Matthew R Beymer, Ryan M Kofron, Robert K Bolan, Wilbert C Jordan

Open Forum Infect Dis· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Raphael J Landovitz, Sue Li, Joseph J Eron, Beatriz Grinsztejn, Halima Dawood, Ryan Kofron

Lancet HIV· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
Raphael J Landovitz, Sahar Z Zangeneh, Gordon Chau, Beatriz Grinsztejn, Joseph J Eron, Ryan Kofron

Clin Infect Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting injectable cabotegravir for the prevention of HIV infection.
Meredith E Clement, Ryan Kofron, Raphael J Landovitz

Curr Opin HIV AIDS· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.
David Goodman-Meza, Matthew R Beymer, Ryan M Kofron, K Rivet Amico, Christina Psaros

AIDS Care· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Raphael J Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Ryan Kofron

PLoS Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County.
Matthew R Beymer, Ryan M Kofron, Chi-Hong Tseng, Robert K Bolan, Risa P Flynn

Int J STD AIDS· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
Raphael J Landovitz, Matthew Beymer, Ryan Kofron, Kathy Rivet Amico, Christina Psaros

J Acquir Immune Defic Syndr· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California.
Matthew R Beymer, Robert E Weiss, Robert K Bolan, Ryan M Kofron, Risa P Flynn

Open Forum Infect Dis· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The promise and pitfalls of long-acting injectable agents for HIV prevention.
Raphael J Landovitz, Ryan Kofron, Marybeth McCauley

Curr Opin HIV AIDS· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Audio-Enhanced Tablet Computers to Assess Children's Food Frequency From Migrant Farmworker Mothers.
Jill F Kilanowski, Erika S Trapl, Ryan M Kofron

Infant Child Adolesc Nutr· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis